To BRAF or not to BRAF: Is that even a question anymore?

Journal of Neuropathology and Experimental Neurology

Volumn 72, Issue 1, 2013, Pages 2-7

  Horbinski, Craig ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

BRAF; FISH; Fusion; Ganglioglioma; Pilocytic astrocytoma; Pleomorphic xanthoastrocytoma; V600E

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; SELUMETINIB; VALINE; VEMURAFENIB;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ASTROCYTOMA; BRAIN TUMOR; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CEREBELLUM TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; DIFFERENTIAL DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE INSERTION; GENE MUTATION; GENETIC SCREENING; GLIOMA; HUMAN; MANDATORY TESTING; MELANOMA; MICROSCOPY; ONCOGENE; ONCOGENE BRAF; OPTIC NERVE GLIOMA; PILOCYTIC ASTROCYTOMA; PILOMYXOID ASTROCYTOMA; PLEOMORPHIC XANTHOASTROCYTOMA; POINT MUTATION; PRIORITY JOURNAL; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANIMALS; BRAIN NEOPLASMS; CHILD; GLIOMA; HUMANS; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION;

EID: 84871995861     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e318279f3db     Document Type: Review

References (42)

1. Keller TH, Pichota A, Yin Z. A practical view of ''druggability.'' Curr Opin Chem Biol 2006;10:357-61
2. Tatevossian RG, Lawson AR, Forshew T, et al. MAPK pathway activation and the origins of pediatric low-grade astrocytomas. J Cell Physiol 2010;222:509-14
3. Jacob K, Quang-Khuong DA, Jones DT, et al. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Clin Cancer Res 2011;17:4650-60
4. Maurer G, Tarkowski B, Baccarini M. Raf kinases in cancerVroles and therapeutic opportunities. Oncogene 2011;30:3477-88
5. Sanoudou D, Tingby O, Ferguson-Smith MA, et al. Analysis of pilocytic astrocytoma by comparative genomic hybridization. Br J Cancer 2000; 82:1218-22
6. Bar EE, Lin A, Tihan T, et al. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol 2008;67:878-87
7. Pfister S. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008;118: 1739-1749
8. Sievert AJ, Jackson EM, Gai X, et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol 2009;19:449-58
9. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008;68:8673-77
10. Cin H, Meyer C, Herr R, et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 2011;121:763-74
11. Forshew T, Tatevossian RG, Lawson AR, et al. Activation of the ERK/MAPK pathway: A signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 2009;218:172-81
12. Jones DT. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009;28:2119-23
13. Dimauro T, David G. Ras-induced senescence and its physiological relevance in cancer. Curr Cancer Drug Targets 2010;10:869-76
14. Raabe EH, Lim KS, Kim JM, et al. BRAF activation induces transformation and then senescence in human neural stem cells: A pilocytic astrocytoma model. Clin Cancer Res 2011;17:3590-99
15. Hawkins C, Walker E, Mohamed N, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 2011;17:4790-98
16. Gronych J, Korshunov A, Bageritz J, et al. An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. J Clin Invest 2011;121:1344-48
17. Horbinski C, Nikiforova MN, Hagenkord JM, et al. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol 2012;14:777-89
18. Horbinski C, Hamilton RL, Nikiforov Y, et al. Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol 2010;119:641-49
19. Lawson AR, Tatevossian RG, Phipps KP, et al. RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort. Acta Neuropathol 2010;120:271-73
20. Ida CM, Lambert SR, Rodriguez FJ, et al. BRAF alterations are frequent in cerebellar low-grade astrocytomas with diffuse growth pattern. J Neuropathol Exp Neurol 2012;71:631-39
21. Lin A, Rodriguez FJ, Karajannis MA, et al. BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol 2012;71:66-72
22. Tihan T, Ersen A, Qaddoumi I, et al. Pathologic characteristics of pediatric intracranial pilocytic astrocytomas and their impact on outcome in 3 countries: A multi-institutional study. Am J Surg Pathol 2012;36:45-55
23. Huang H, Okamoto Y, Yokoo H, et al. Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene 2004;23:6012-22
24. Hasselblatt M, Riesmeier B, Lechtape B, et al. BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults. Neuropathol Appl Neurobiol 2011;37:803-6
25. Johnson MW, Eberhart CG, Perry A, et al. Spectrum of pilomyxoid astrocytomas: Intermediate pilomyxoid tumors. Am J Surg Pathol 2011; 34:1783-91
26. Dahiya S, Yu J, Kaul A, et al. Novel BRAF alteration in a sporadic pilocytic astrocytoma. Case Report Med 2012;2012:418672
27. Setty P, Gessi M, Waha A, et al. Sensitive determination of BRAF copy number in clinical samples by pyrosequencing. Diagn Mol Pathol 2011; 20:148-57
28. Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 2005;115:94-101
29. Tian Y, Rich BE, Vena N, et al. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn 2011;13:669-77
30. Korshunov A, Meyer J, Capper D, et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 2009;118:401-5
31. Schiffman JD, Hodgson JG, VandenBerg SR, et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 2010;70:512-19
32. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extracerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397-405
33. Nicolaides TP, Li H, Solomon DA, et al. Targeted therapy for BRAF V600E malignant astrocytoma. Clin Cancer Res 2011;17:7595-604
34. Basto D, Trovisco V, Lopes JM, et al. Mutation analysis of BRAF gene in human gliomas. Acta Neuropathol 2005;109:207-10
35. Knobbe CB, Reifenberger J, Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 2004;108:467-70
36. Dias-Santagata D, Lam Q, Vernovsky K, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: Diagnostic and therapeutic implications. Plos one 2011;6:17948
37. Badiali M, Gleize V, Paris S, et al. KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults. Brain Pathol. 2012;22:841-47
38. Dougherty MJ, Santi M, Brose MS, et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 2010;12:621-30
39. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011;122:11-19
40. Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009;118:599-601
41. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
42. Poulikakos PI, Rosen N. Mutant BRAF melanomasVdependence and resistance. Cancer Cell 2011;19:11-15.